Intellectual Property News

AVID vs. Datamars litigation settled, AVID vs. Allflex trial date set

FOR IMMEDIATE RELEASE
November 24, 2008

San Diego, CA--
The lengthy intellectual property litigation between AVID Identification Systems, Inc. and Datamars et al., taking place in the U.S. Federal Court, at Marshall, Texas, has been settled by the litigants.

Meanwhile, a trial date has been set by the court in substantially similar litigation taking place in the U.S. District Court, Central District of California, Case #5:06-cv-01109-SGL-OP, AVID Identification Systems Inc. vs. Allflex et al. That trial is scheduled to begin on August 10, 2010.

Jury Finds Against Datamars: Claims of false advertising and patent infringement found valid

FOR IMMEDIATE RELEASE

June 7, 2006

St. Louis, MO--
Avid Identification Systems, Inc. has won a significant litigation victory in the United States. A jury found that two competitors have infringed on Avid’s technology and had made false advertising claims that harmed consumers. The jury concluded that there was in excess of $6 million in damages caused by European based Datamars SA and its wholly owned U.S. subsidiary, Crystal Import Corporation.

The jury unanimously found that Datamars SA and Crystal Import Corporation not only infringed, but willfully infringed three patents held by Avid for its core RFID technology, predominantly used today by Avid for identifying pets and re-uniting lost pets with their families. The infringing products include ISO 134.2 kHz pet identification microchips and readers manufactured by Datamars and reported in DVM Magazine as being distributed in the United States by Bayer Health Care, Animal Health Division.

Banfield, the Pet Hospital had previously been enjoined from selling the same ISO products last year by the Superior Court in San Diego, California due to " the risk of great, irreparable harm for which legal remedies are inadequate, specifically the increased potential for pets to be euthanized while their owners believe them to be safe. "

The jury also found Datamars SA and Crystal Import Corporation liable for false advertising under the Lanham Act for making false claims about the effectiveness of their ISO products in locating and returning lost pets with their owners.

During the second day of trial, two other defendants in the lawsuit, Philips Semiconductors Inc. and Philips Semiconductors Manufacturing Inc., settled their case and licensed Avid’s patents in suit for restricted applications (non companion animal).

The trial, which was held in U.S District Court, Eastern District of Texas in Marshall, Texas, lasted six days. The jury of unbiased citizens from varied backgrounds deliberating for less than five hours before delivering their unanimous decisions.

The microchip sold by Datamars SA and Crystal Import Corporation operate on the European ISO technology based on 134.2 kHz, which is not compatible with the American installed base of readers and microchips. In February 2004, when the products were introduced into the U.S., there were only 600 ISO microchip readers at shelters nationwide capable of reading the 65,000 pet microchips sold at the ISO 134.2 frequency. In contrast, Avid and other manufacturers have supplied U.S. shelters and vets with approximately 100,000 readers that can read America’s the installed base of microchips in more than 12 million pets, including dogs, cats, birds and horses.

"The infrastructure to read pet microchips and ultimately return pets to their owners must be in place before a different product is introduced," stated Dr. Hannis L. Stoddard III, president and founder of Avid as well as a practicing veterinarian and hospital owner. "Consumers trust that microchips will improve the probability of a safe return of lost animals and if a product doesn’t do that, pets are put at risk. ... The jury’s verdict also sends a cautionary message to microchip system users to carefully evaluate claims made about the 134.2 kHz RFID systems."

Several issues are still pending before the court, including a decision regarding an injunction against Datamars SA and Crystal Import Corporation that would prevent the companies from selling their infringing products in the U.S. A decision is expected no later than mid-July. Avid was represented by Fish & Richardson, with Juanita Brooks as lead counsel. "A company’s patents are an asset of great value and must be protected, especially when another company willfully infringes them," says Ms. Brooks. "Pets are an important part of most American families, and pet owners must be protected against false advertising, particularly when their pet’s lives are put at risk. The jury understood the significance of both of these issues and came to a fair and equitable decision," concludes Ms. Brooks, who has more than 25 years litigating high profile complex technology cases and more recently animal wellbeing issues.

For more info about AVID, visit www.avidid.com
For more info about Fish & Richardson, visit www.fr.com

Court halts nationwide sale of ISO FDX-B chips

FOR IMMEDIATE RELEASE

November 4, 2004

San Diego, California-- The San Diego Superior Court yesterday issued a preliminary injunction blocking Medical Management Interational, dba Banfield, ThePet Hospital, from selling or advertising ISO FDX-B microchips for pet ID. Banfield Pet Hospitals are located in PETsMART stores throughout the United States.

If Banfield wants to resume selling or promoting its RecoveryChip, its written promotional materials and advertisements must first be submitted to the court, in order to ensure that they disclose that "134.2 kHz electronic identification tags . . . cannot be read by the vast majority of scanners in U.S. shelters." Judge William C. Pate noted that "the potential for serious, irreparable harm warrants the issuance of a mandatory preliminary injunction . . . specifically the increased potential for pets to be euthanized while their owners believe them to be safe."

The order is the result of a consumer protection lawsuit filed in May 2004, after Banfield's distribution of its chips triggered a strong response by the pet shelter community.

Pet microchipping systems use a scanner (or reader) to read a small microchip that is injected under the skin of a pet. The 134.2 kHz microchip, used in several foreign countries, cannot be read by scanners used by most American veterinarians and shelters.

The court also ordered Banfield "to notify all purchasers of its RecoveryChip, or any other 134.2 kHz electronic identification tags it has sold, as well as all veterinarians to whom it has recommended these products" of the chip's limitations.

The injunction requires Banfield's notification to be approved by the Court, and to state that only certain, specifically listed shelters are equipped with scanners that can read Banfield's chip. The notification also must disclose that the mere fact that shelters have such scanners "does not guarantee that the shelters will actually use those scanners on lost pets." Finally the notification must further disclose "that the majority of shelters presently use a scanner that will not detect or read [Banfield's] implanted chip."

"Judge Pate's order may very well save pet's lives," said Hannis L. Stoddard III, DVM and president of AVID, one of the parties that brought the lawsuit. AVID manufactures Friend Chips, a microchip pet ID tag that has been used successfully throughout the country to reunite pets with their families for years.

"Today's decision . . . is an important step in stopping and remedying an advertising campaign that the court recognized was likely to deceive consumers and create a risk of unnecessarily euthanized pets," states Daniel Pascucci of Fish & Richardson, counsel for AVID and veterinarian Robert Stonebreaker, D.V.M., who filed the consumer protection lawsuit against Banfield.

For further information, please contact:
Dr. Dan Knox , Director Companion Animal Field Operations, 314.487.5842, Avidsaveslives@AvidID.com
Teresa Y. Warren, TW2 Marketing, 619.582.5750, twarren@tw2marketing.com

For more info about AVID, visit www.avidid.com
For more info about Fish & Richardson, visit www.fr.com

Digital Angel sues Allflex and Datamars

FOR IMMEDIATE RELEASE

October 20 , 2004

Minneapolis, USA --
Digital Angel Corporation, today filed a Complaint against Allflex USA, Inc. and its distributor Pet Health Services (USA) Inc. alleging infringement of its U.S. Pat. No. 5,211,129 entitled “Syringe Implantable Identification Transponder. ”

Digital Angel alleges that both the FDX-A and FDX-B transponders offered by Allflex infringe the ë129 patent and that the transponders currently being sold by Allflex, manufactured by Sokymat, are not covered by the licensing agreement previously entered into between Allflex and Digital Angelís predecessor Destron Fearing.

Separately, Digital Angel Corporation filed a Complaint against Datamars Inc., Datamars SA, The Crystal Import Corporation and Medical Management International, Inc., which does business as Banfield The Pet Hospital alleging infringement of the same U.S. Pat. No. 5,211,129.

The Complaint states that Datamars approached Digital Angel on several occasions seeking a license. Digital Angel offered Datamars a worldwide license. Datamars rejected the offer. The 5,211,129 patent is valid only in the United States.

AVID Wins Patent Infringement Suit Against Pethealth

FOR IMMEDIATE RELEASE

October 14 , 2004

NORCO, California --
The federal district court in Madison, Wisconsin recently ruled in a suit brought by AVID Identification Systems, Inc., that certain products used and distributed by Pethealth Services (USA) Inc. infringe a patent owned by AVID. AVID and Pethealth settled the remaining portions of the case.
Judge John C. Shabaz Order ruled: “IT IS ORDERED that Plaintiff’s motion for summary judgment of infringement is GRANTED…”, and “IT IS FURTHER ORDERED that defendant’s motion for summary judgment of non-infringement is DENIED.”
“We anticipate that this ruling will help validate the 125 kHz based microchip technology widely and commonly used in the U.S. for pet identification.” said AVID founder Hannis L. Stoddard III, D.V.M., “AVID believes that the U.S. pet microchipping and recovery systems were jeopardized recently by several reckless attempts to introduce an incompatible 134.2 kHz based microchip technology.”
AVID, a pioneer in radio frequency identification (“RFID”) technology since 1985, is seeking to prevent Pethealth from making, using, selling, or inducing the wrongful use of infringing products. AVID has eighteen U.S. patents and corresponding foreign patents that cover its advances in RFID scanner and microchip transponder technology.
The AVID RFID system uses a scanner to read the identification code in a microchip transponder. Microchips are used to identify and trace animals and inanimate objects around the world. RFID is the emerging technology for many enhanced applications including; security access control, supply chain management, car immobilizers, automotive speed passes, counterfeit protection, asset management and inventory control.
Chadd Taylor of Kirkland & Ellis and lead litigation counsel for AVID in this case said, “This is a strong step towards validating the hard work that AVID has put into developing this technology. AVID will continue to aggressively protect its valuable intellectual property.”
The Wisconsin ruling is not the first to vindicate AVID’s intellectual property rights. On June 4, 2004, United States Court of Appeal for the Federal Circuit ruled in favor of AVID, against infringers Global ID Systems, Inc. and Douglas Hull. The defendants had been found liable for unfair competition, trademark infringement and patent infringement. The infringement was ruled to be willful and unexcused, which doubled the damages awarded to AVID. David B. Abel of Squire, Sanders & Dempsey was the successful lead litigator in the Global ID case.
In a separate patent infringement case, in May of this year, AVID filed suit in East Texas against Philips Electronics North America Corp., Medical Management International, Inc. dba Banfield the Pet Hospital, Datamars, Inc. and others, related to AVID’s scanning and microchipping technology. AVID is represented by Fish & Richardson P.C. in this matter.
Advising AVID is Professor Mark A. Lemley, William H. Neukom Professor of Law, Director of the Stanford Program in Law, Science and Technology, of counsel Keker & Van Nest LLP.

For further information, please contact:
Dr. Dan Knox , Director Companion Animal Field Operations, 314.487.5842, Avidsaveslives@AvidID.com
Loran Hickton, Salmon Creek Public Relations Inc., 360.571.5560, lhickton@salmoncreek.com

For more info about AVID, visit www.avidid.com
For more info about Fish & Richardson, visit www.fr.com
For more information about Kirkland & Ellis, visit www.kirkland.com
For more information about Squire, Sanders & Dempsey, visit www.ssd.com
For more information about Keker & Van Nest, visit www.kvn.com

Banfield The Pet Hospital stops marketing ISO microchip

FOR IMMEDIATE RELEASE
May 14, 2004


A spokesperson for Banfield The Pet Hospital, which has locations in PetSmart stores throughout the United States, has confirmed that the company has stopped marketing their ISO FDX-B microchips.

On April 21, a pit bull was euthanized in a Virginia shelter, because the animal’s Banfield-supplied chip was not compatible with the shelter’s reader. Inquiries by journalists confirmed that none of the area’s shelters was using compatible readers.

Mark Kumpf, President of the Virginia AnimalControl Association, said: “HSUS, ASPCA, NACA, and other national animal care and control organizations have issued a warning to pet owners that new ISO microchips offered by Banfield and other pet hospitals may place your pets at risk.” Rick Collord, Former Chairman, Society of Animal Welfare Administrators, Microchip Committee, explained that “With the use of this incompatible technology, and without scanners in widespread use that can read all three chips accurately, thoroughly and precisely, the new ISO chip is a detriment."

Dr. Jamie Rees of Banfield stated that “Banfield has chosen the new ISO chip and scanner because it is the new technology that is what the rest of the world is using.”

Although ISO FDX-B microchips are being used in some European countries and parts of Australia, acceptance of ISO FDX-B microchips is not universal and the standard on which they are based continues to generate controversy, in part due to concerns about ID code duplication.

AVID sues suppliers of ISO microchips for infringement of its U.S. patents

FOR IMMEDIATE RELEASE
May 13, 2004


On May 3, California-based microchip vendor AVID initiated legal action in Marshall, Texas against several defendants for infringing U.S. Pat Nos. 5,214,409 and 5,499,017. Case #2:04-cv-00183-TJW, Hon. T. John Ward, presiding, lists as defendants:
Phillips Electronics North America Corp.
Koniklijke Phillips Electronics NV
The Crystal Import Corp.
Medical Management International Inc.
Datamars Inc./Datamars SA.

Medical Management International Inc., does business as Banfield the Pet Hospital.
Crystal Import Corp. markets Datamars products in the United States and lists the same Pelham, Alabama contact address as Datamars USA.

The legal action alleges that Datamars ISO transponders (whose 15-digit ID code begins with the digits 981...) incorporate the allegedly infringing “Hitag S” integrated circuit manufactured by Phillips.

Furthermore the complaint in Texas also alleges infringement of AVID's U.S. Patent No. 5,235,326 . This claim affects ISO-compatible readers marketed by Datamars. In the event AVID prevails in its litigation, AVID would be entitled to demand that use of infringing product cease, meaning that readers capable of reading the Banfield/Crystal Import/Datamars product could bew removed from shelters.

AVID has also started separate legal action against Allflex USA Inc. and its
distributor, PetHealth Services in the US District Court of Wisconsin
(Madison), in Case 04-C-0067-S, Filed Feb. 11, 2004,the Hon. John C. Shabas presiding.
This case alleges infringement of US Pat. Nos. 5,266,926 and 5,559,507 with respect to the design and construction of the reader antenna. In the event AVID prevails in its litigation, AVID would be entitled to demand that use of infringing product cease, meaning that readers capable of reading the Allflex product could be removed from shelters.

The litigation by AVID could have repercussions beyond U.S. borders since the patents in question have foreign counterparts in Europe, Australia and elsewhere, meaning that similar litigation could impact the availability of these ISO FDX-B microchips and readers in those countries.

Sokymat taper siste appell

FOR UMIDDELBAR FRIGIVELSE

17. juli 2003

München, Tyskland --
Den 7. juli 2003 har Delstatshøyesterett i München, Tyskland avsagt en kjennelse som går imot Sokymat SA og Åke Gustafson i saken som gjelder oppfinnerrettigheter og eierskap til det europeiske patentet Nr. 0588944 (sak nr. 6 U 2535/02). Dommen medfører at de krav som er dekket av europeisk patent nr. 0588944, som ble utstedt til Algernon Promotions Ltd. 23.12.2002 kan håndheves uten begrensninger av patentets eiere og deres lisenspartnere, Algernon Promotions Ltd. og Trovan. Patent nr. 0588944 beskriver krav som relaterer til en ”direct bonding” teknologi som er utviklet av ingeniører fra Trovan.

Sokymat var opprinnelig underleverandør for Trovan og ble da gjort kjent med Trovans teknologi under en avtale om hemmeligholdelse av informasjoner utvekslet mellom firmaene. Uten Trovans vitende startet Sokymat å utvikle produksjonskapasitet for produkter basert på Trovans patenterte ”direct bonding”-teknologi samt annen konfidensiell informasjon Sokymat hadde fått under vtalen om hemmeligholdelse av informasjoner mottatt. Sokymat solgte produktene som deres egne produkter.

Noen av de primære bruksområdene hvor Sokymat har solgt produkter basert på ”direct bonding”-teknologi omfatter: produkter for bilindustrien, spesielt elektroniske tenningslås, anti-tyveri sikkerhetsanordninger, elektronisk merking av sykler, motorsykler, båter, elektronisk utstyr osv., elektronisk adgangskontroll samt individmerking innen fiskeri, husdyrbruk og merking av selskapsdyr.

Det pågår en tilsvarende rettslig prøving av krav fra Algernon/ Trovan mot Sokymat SA i USA angående et patent som bare dekker USA. ”Vi beklager situasjonen for Sokymats kunder som i en årrekke kan ha brukt produkter som er i konflikt med våre patentrettigheter. Vi vil imidlertid anstrenge oss for å finne løsningen med de ulike firmaene på en individuell basis” sa Mr. Salomon på vegne av Trovan Ltd. da den endelige domsslutningen ble gjort kjent.

Algernon/ Trovan har en rekke europeiske patenter som dekker virkemåte og produksjon, med ytterligere patentsøknader som er sendt inn.

For additional information in the United States please contact:

Electronic Identification Devices, Ltd.
Barbara Masin
e-mail: bmasin@eidltd.com

Sokymat Final Appeal denied

FOR IMMEDIATE RELEASE

July 17, 2003

Munich, Germany--
The Oberlandesgericht (Superior District Court) in Munich, Germany has ruled against Sokymat SA and Ake Gustafson, on July 17, 2003, with respect to the inventorship and ownership of European Patent No. 0588944 (case no. 6 U 2535/02). The ruling renders the claims of European Patent No. 0588944, which issued to Algernon Promotions Ltd. on 23.12.02, fully enforceable by its owners and licensees, Algernon Promotions Ltd., and Trovan, Ltd. Patent No. 0588944 lists claims relating to the direct bonding technology developed by Trovan engineers.

Sokymat was initially retained as a subcontractor to Trovan and learned about the Trovan technology under the terms of a Non-Disclosure Agreement between the parties. Unbeknownst to Trovan, Sokymat proceeded to develop manufacturing capability for products based on Trovan’s patented direct bonding technology and other confidential information revealed under the Non-Disclosure Agreement and to sell products on its own account.

Some of the primary applications Sokymat is supplying with product utilizing the direct-bonding technology are: automotive applications, specifically ignition immobilizers; anti-theft security applications, involving the chipping of items such as bicycles, motorcycles, boats, electronics etc.; access control applications as well as fisheries, livestock and companion animal applications.

There is a parallel, ongoing litigation by Algernon/Trovan against Sokymat SA in the United States concerning a patent covering the U.S. market only. “We are sorry for Sokymat customers who might have been using infringing products over the years. However, we will make an effort to reach accommodations with interested parties on an individual basis,” Mr. Salomon said, on behalf of Trovan, Ltd., upon publication of the final verdict.

The Algernon/Trovan European patent portfolio consists of a number of manufacturing and operational patents, with additional patents pending.

For additional information in the United States please contact:

Electronic Identification Devices, Ltd.
Barbara Masin
e-mail: bmasin@eidltd.com

Patent contested by Sokymat issues to Trovan’s benefit

FOR IMMEDIATE RELEASE

February 24, 2003

Munich, Germany --
Trovan, Ltd. is pleased to announce that on January 2, 2003 the European Patent Office granted patent EP 0588 944, entitled “An Improved Miniature Transponder Device,” to Algernon Promotions Ltd. Trovan, Ltd. holds the exclusive license for this patent from Algernon.

Sokymat SA has attempted to prevent the issuance of this patent for several years through the German courts. Sokymat argued that Ake Gustafson was the inventor of the technology described in the patent, and subsequently back-pedalled to claim that he was at least co-inventor of the technology in question. Upon examination of the evidence, the Court has rejected Sokymat’s claims.

Separately, Sokymat has lost multiple appeals in U.S. courts relating to the U.S. counterpart of patent EP 0588 944.

Sokymat SA has marketed infringing products based on Trovan’s technology for a number of years. Patent EP 0588 944 describes the so-called “direct bonding” technology that has been used in a number of core Sokymat products including ignition immobilizers sold to the automotive industry and miniature glass-encapsulated animal implantable transponders. These products have been sold by Sokymat customers under their own brand names as well as by Sokymat directly.

Trovan and its partners will vigorously enforce their rights to the technology against infringers.

For additional information in the United States please contact:

Electronic Identification Devices, Ltd.
Barbara Masin
telephone: 805-565-1288
fax: 805-565-1127
e-mail: bmasin@eidltd.com

Trovan transponders to identify new electronic ski binding

FOR IMMEDIATE RELEASE
January 3, 2003

London --
Trovan Ltd. has reached agreement with Implementors Inc., which is soon to launch the manufacture of a ground-breaking electronic ski binding, to insert Trovan microchips in the ski bindings. The purpose is to track ski bindings in rental shops and to provide anti-theft protection, as a value-added service to customers.

In future, Implementors envisions that the inserted Trovan microchip can be used as a skipass.

For information on the Implementors electronic ski binding, please see: http://www.electronic-ski-binding.com

For additional information in the United States please contact:

Barbara Masin
Electronic ID Devices Ltd.
telephone: (805) 565-1288
bmasin@EIDLtd.com

Judgment against Sokymat S.A. reaffirmed on February 20, 2001

FOR IMMEDIATE RELEASE
March 18, 2002

Santa Barbara--
On February 20, 2001, the United States District Court, Central District of California, has rejected Sokymat S.A.'s appeal of its earlier ruling dated June 9, 1999, in which the Court has affirmed the validity, enforceability and inventorship of U.S. Patent No. 5,281,855. The Court has determined that the Patent issued to Trovan, Ltd. and owned by Algernon Promotions Ltd (the Plaintiffs) has been infringed upon by Sokymat S.A. and others.

Sokymat S.A., which has its main offices in Granges, Switzerland, manufactures ignition immobilizer systems for the automotive industry, as well as industrial and animal RFID products sourced to and resold by other vendors under a variety of brand names. The patented technology in question in this litigation has been broadly used by Sokymat S.A. across its product range.

Mr. Joseph Masin, President of Electronic Identification Devices, Ltd. the North American distributors of the Trovan, Ltd. products said "We are pleased to have our position vindicated by the Court. The Courtís decision unequivocally confirms the enforceability of the Patent describing this important direct bonding technology by Algernon and Trovan, which has been disputed previously by Sokymat. The patent owners intend to continue to enforce their intellectual property rights and seek recovery for past damages from all manufacturers of infringing products and of infringing components as well as from users who have previously been notified."

Trovan, Ltd. is an RFID industry leader controlling a comprehensive portfolio of patented technologies. Algernon and Trovan consider their patented technologies to be an important strategic and competitive asset.

For additional information in the United States please contact:

Electronic Identification Devices, Ltd.
Barbara Masin
telephone: 805-565-1288
fax: 805-565-1127
e-mail: bmasin@eidltd.com

NTRU announces GenûID; First Complete Security Solution Designed Specifically for Radio Frequency Identification and Contactless Applications



FOR IMMEDIATE RELEASE
March 18, 2002

Burlington, Mass. -- NTRU's Small, Fast, Strong Security Technology Enables Robust Public Key Security on Space-Constrained RFID Devices and Contactless Cards

NTRU, the only provider of strong security that fits everywhere, today announced the release of NTRU GenûID?, the first practical public key security solution designed for securing RFID (radio frequency identification) and contactless applications of all types. Based on the most fundamental breakthrough in cryptography in 20 years, NTRU GenûID operates hundreds of times faster than legacy systems while requiring only a fraction of the footprint. As a result, RFID and contactless application vendors and developers finally have the option to add powerful security to their solutions without compromising cost or performance.

"RFID and contactless technologies are already proven in many industries. One of the barriers to widespread application adoption has been a lack of affordable, efficient and powerful security," said Deepak Shetty, RFID industry analyst at Frost and Sullivan. "Products like NTRU's GenûID will open up new markets and opportunities for RF and contactless application developers, vendors and RF device users."

Until NTRU GenûID, no practical security solution existed for RFID and contactless applications. Legacy public key technology was too slow, too expensive and too power-hungry, while symmetric key systems have too many security vulnerabilities and scalability problems. The size and speed advantages of GenûID‚s next-generation public key security allow it to operate under the very constrained size and power consumption requirements demanded by RFID and contactless devices. NTRU GenûID enables manufacturers to tap new markets, customers and revenue opportunities.

"NTRU's GenûID cryptosystem enables manufacturers and developers to create RFID products that are high-performing, cost-effective and secure," said Bruce Del Porte, RFID Marketing Manager at Atmel. "Atmel Corporation is a leading supplier of sophisticated semiconductors and GenûID will create a host of new opportunities, allowing us to strengthen our position in the RFID market."

The addition of robust, scalable and inexpensive security to RFID and contactless devices and platforms offers increased performance and substantially reduced fraud risk to high-value applications such as payment, ticketing and transit. It also enables contactless applications that securely transmit personal data, like personal ID cards and biometrics. In transit applications, for instance, NTRU GenûID enables a passenger to quickly pay for admission and other services with a card or key fob, without fishing through pockets and wallets for cash. For contactless applications, GenûID enables identification, authentication and physical access control, providing strong security without inconveniencing the consumer. GenûID protects an individual‚s personal information stored on a card or other contactless device, preventing unauthorized access or alteration. Typical usage examples are airline security checkpoints and border crossings.

"NTRU GenûID is the only product line that meets the unique security requirements of constrained RFID and contactless environments. NTRU GenûID eliminates the traditional trade-offs between security, cost and performance," said Scott Crenshaw, NTRU CEO. „NTRU GenûID allows strong security to be implemented in the smallest RFID devices, even tokens or tags that cost as little as $0.50. This opens up markets for RFID and contactless applications, bringing the technology to high-value and sensitive transactions that were previously impossible to secure.

NTRU GenûID Unique Features and Benefits

NTRU GenûID offers RFID and contactless application vendors and OEMs powerful encryption and digital signature functionality that is easy to implement and tailor to specific application needs. It is a complete end-to-end solution, supporting all functions and components along the entire RF and contactless value chain. NTRU GenûID consists of the NTRU GenûID Hardware Core, a VHDL core enabling incorporation of public key security into the most cost- and space-constrained semiconductors, the NTRU GenûID Software for Chip Cards, enabling public key security to run on low-cost microcontrollers without the added cost, size and power consumption of cryptographic co-processors, and GenûID toolkits for readers and backend servers. NTRU‚s GenûID family makes it fast and easy for semiconductor vendors, application developers and systems integrators to include strong security in their products.

Higher security--For the first time, GenûID brings strong, affordable public key security to the RFID and contactless markets. Public key security delivers numerous benefits. It is substantially more secure than alternatives, delivering enhanced fraud protection. For example, with systems not using public key security, the compromise of just one reader compromises the security of the entire system. NTRU GenûID eliminates this threat. GenûID also makes key management much simpler and less expensive, while increasing system scalability.

Multi-function applications--With new levels of security now possible, RFID and contactless vendors have new opportunities to develop multi-function applications, like ticketing and point of sales transaction, with higher revenue and profit potential.

Faster performance--GenûID eliminates the wait users can experience, for example, when completing credit card transactions or gaining access to border crossings or other secure areas. GenûID is actually faster in software than competitive systems are with hardware acceleration. Convenience and speed are the keys to end user satisfaction; GenûID brings performance to new levels without compromising security.

Longer operational range--GenûID consumes significantly less power than other public key security technologies, dramatically expanding the range of RFID and contactless tokens. For example, this allows a rider to enter a transit system without removing the ticket from his wallet. Traditionally, the physical, engineering and regulatory hurdles made increasing read range impractical; now, it can be accomplished simply by switching to NTRU GenûID.

Lower cost--GenûID‚s efficiency means smaller footprint and significantly less expensive manufacturing. This enables wider deployment of secure RFID applications, increasing revenues and profits, while providing end users greater convenience and security. These are cost-driven markets, where NTRU GenûID can make the difference between success and failure.

Fast time to market/Easy to integrate--NTRU GenûID integrates quickly and easily into semiconductors (whether fixed logic or microcontroller-based), readers and back-end servers, enabling vendors to rapidly bring much needed functionality to market. This functionality differentiates products and changes the competitive profile of RFID and contactless offerings. NTRU GenûID simplifies the process of providing secure RFID and contactless applications, and allows vendors to increase market share and gain significant competitive advantages.

Availability NTRU GenûID products are available immediately.

About NTRU

NTRU is the only provider of strong security that fits everywhere. Based on the most fundamental innovation in cryptography in more than 20 years, NTRU eliminates historic price, performance and usability tradeoffs in security. NTRU delivers strong, fast security that operates with minimal power consumption and fits into a tiny footprint, making it easy for customers to build devices that people trust. NTRU security is gaining widespread adoption in the radio frequency identification (RFID), mobile communications, multimedia and embedded markets. Headquartered in Burlington, Mass., NTRU is backed by Texas Instruments, Sony Corporation, Macrovision, Lehman Brothers Venture Capital, Investor AB, Granite Ventures, Greylock, CTT and 3i. For more information, visit www.ntru. com .

###

Note: NTRU security products are protected by U.S. Patent No. 6,081,597; other U.S. and foreign patents pending.

For additional information in the United States please contact:

Heather A. Baker
Schwartz Communications, Inc.
telephone: (781) 684-0770
fax: (617) 684-6500

Judgment in Favor of Trovan September 8, 2000, on U.S. Patent no. 5,281,855 Litigation Trovan et al. v. Sokymat Case No. 99-1474, 1488

FOR IMMEDIATE RELEASE
September 11, 2000

Santa Barbara --
The United States Court of Appeals for the Federal Circuit has confirmed the validity of U.S. Patent no. 5,281,855, and has confirmed that infringement of said patent has been conceded by Sokymat S.A. This ruling was in response to an appeal filed by Sokymat suggesting that the trial court abused its discretion in ruling in Trovan's favour.

The second argument by Sokymat concerned the issue of inventorship of U.S. Patent no. 5,281,855. This issue has been remanded by the Appeals Court for resolution by the District Court.

The cross appeal by Trovan et al. concerning the ownership of Ake Gustafson's U.S. Patent No. 5,572,410, which the District Court determined was owned by Mr. Gustafson, has been denied.

In unrelated legal action by Metget of Sweden, claims 12 - 24 of the European counterpart to the above-mentioned Gustafson U.S. patent no. 5,572,410, the EP 0573 469, have been ruled unenforceable by the German court, due to the existence of prior art. The value of this patent remains questionable.

For additional information in the United States please contact:

Electronic Identification Devices, Ltd.
Barbara Masin
telephone: 805-565-1288
fax: 805-565-1127
e-mail: bmasin@eidltd.com

Pfizer, Inc. Permanently Enjoined From Using Trovan Mark for its Antibiotic and Must Cancel its Mark in Trovan, Ltd. v. Pfizer, Inc. Trademark Infringement Case

Final Judgment of $143 Million entered against Pfizer, Inc.

FOR IMMEDIATE RELEASE
February 25, 2000

Los Angeles, CA. --
US District Court Judge Lourdes G. Baird yesterday issued a permanent injunction against Pfizer, Inc. (NYSE:PFE), ordering the company to stop using the Trovan® mark as of October 16, 2000 and, until then, to "take immediate steps to...destroy all written marketing and promotional materials...and to stop making use of the word "TROVAN." The court canceled Pfizer's registration of the TROVAN mark with the US Patent Office, effective immediately. Final judgment in the amount of $143 million was entered against Pfizer, and the case sets an internationally important benchmark for trademark infringement and unfair competition cases [Trovan, Ltd. v. Pfizer, Inc., Case No. 98-0094 LGB (Mcx)].

Among other rulings issued yesterday, the Court declined Trovan's motion for treble damages or Pfizer's profits, finding that Trovan has already been "amply" compensated by the $143 million jury verdict, which was sufficient to "ensure that the guilty party will not return to its former ways and once again pollute the marketplace." The Court ordered Pfizer to pay prejudgment interest on that amount since the date of the October 12,1999 verdict. The case was tried by William E. Levin and Donald L. Abrams with the Laguna Beach, CA. law firm of Levin & Hawes. Percy Anderson and Robert F. Scoular from the Los Angeles office of Sonnenschein Nath & Rosenthal based in Chicago, IL. and Edward J. Horowitz of Los Angeles, CA. recently joined the litigation team.

"We have waited patiently for this day to come," said Joseph Masin, president of Electronic Identification Devices, Ltd., a co-plaintiff in the case, "and are pleased at the outcome. Now, our hope is that Pfizer and its management will be accountable for their wrongdoing and pay this judgment."

"In anticipation of an inevitable appeal and post-judgment motions," explained William E. Levin, "we have assembled an impressive appellate team that is committed every step of the way to protect and defend Trovanís rights. Pfizer may continue to use its vast financial resources to try and defeat justice, but we are confident that Trovan will prevail on appeal, upholding the jury's decision based on overwhelming evidence of blatant and egregious trademark infringement by Pfizer."

The trial began August 18, 1999, and, on September 22, the jury unanimously found Pfizer, Inc. liable for willful, bad faith trademark infringement and unfair competition, awarding Trovan, Ltd. $143 million in general and punitive damages on October 12, 1999. Trovan, Ltd. has used the Trovan® trademark since 1989 to globally market its system of biomedical electronic identification devices, and holds federal trademark registration No. 1649328 issued by the US Patent & Trademark Office in 1991, which became "incontestable" before the suit was filed. Trovan also has several US Food & Drug Administration approvals for its products.

Trovan, Ltd. is a British corporation based in Douglas, Isle of Man and owns the Trovan® trademark; Electronic Identification Devices, Ltd. is a California corporation based in Santa Barbara and is the exclusive North American distributor and a licensee of Trovan® products. Trovan, Ltd. globally markets a system of biomedical devices and also controls a portfolio of valuable patents for technology products such as radio identification systems, and it has recently expanded into pharmaceutical delivery systems.

Press Contact: Kathy Pinckert
Dial: 310-836-8355

Trovan, Ltd. Prevails in Destron Challenge to its Zipquill Technology

FOR IMMEDIATE RELEASE
February 14, 2000

Santa Barbara, CA --
Trovan, Ltd., Electronic Identification Devices, Ltd. and InfoPet Identification Systems prevailed against the appeal by Destron Fearing [NASDAQ: DFCO] of Destron/IDI Inc. v. InfoPet Identification et al., Case No. 99-1373, to the US Court of Appeals for the Federal Circuit, which sought to hold Trovan, EID and InfoPet in contempt for marketing the TROVAN ZIPQUILL implantation technology.

"We are pleased that the courts vindicated our position that the TROVAN ZIPQUILL device is sufficiently different from Destron's U.S. patent no. 5,211,129, that any claim of infringement must be decided in a separate lawsuit," said Joseph Masin, president of Electronic Identification Devices, Ltd. "Destron's attempt to withhold the benefits of a superior animal identification technology from the U.S. market has been thwarted."

U.S. patent no. 5,211,129 held by Destron describes a glass encapsulated transponder that is implanted into animals by means of a syringe.

The TROVAN ZIPQUILL consists of a tiny tubular container which tapers to a sharp point. Inside is space for a small dose of antibiotic paste and/or for an identification transponder. The TROVAN device can be inserted very easily simply by pressing it, sharp point first, into skin with the thumb. No tools are necessary.

"The TROVAN device does not make an incision, or cut, in the skin as a syringe would. Rather it pierces the skin, allowing for rapid closure of the opening after penetration, thereby minimising tissue damage and trauma," said Joseph Masin.
"The TROVAN device is a biologically neutral starch capsule that is water soluble. It dissolves completely and is absorbed by the body within three hours of insertion. The TROVAN ZIPQUILL provides for unprecedented speed of application and eliminates medical waste. There is no transmission of infectious diseases, as can occur in reusable syringes, and no extensive personnel training is required." The TROVAN ZIPQUILL is protected by U.S. patent no. 5,549,560.

The US District Court for the District of Colorado, Judge Zita L. Weinshenk presiding, determined that the question of whether the TROVAN ZIPQUILL infringes Patent No. 5,211,129 is not appropriate in a contempt proceeding. When Destron appealed the court's ruling, the appellate court affirmed the ruling of the Denver court. The Judgment of the appellate court issued on February 10, 2000, one day after oral argument of the appeal.

TROVAN® products are used worldwide by governments, universities, and research facilities for animal identification applications, among others, ranging from the identification of salmon breeding stock to pet-recovery systems to livestock tracking.

Trovan, Ltd. is a British Corporation: Electronic Identification Devices, Ltd. is a California corporation based in Santa Barbara and is the North American distributor and a licensee of TROVAN® products, as is InfoPet Identification Systems, a Minnesota-based corporation.

Contact: Barbara Masin
Dial: 805-565-1288
e-mail: bmasin@eidltd.com

Pfizer, Inc. Must Pay $143 Million to Trovan, Ltd. in Largest Trademark Judgment Ever Awarded in the United States

Pfizer, Inc. must cease using "Trovan" name to market its antibiotic

FOR IMMEDIATE RELEASE
October 12, 1999

Los Angeles, CA -- A 7-panel jury awarded $143 million to Trovan, Ltd. today after 7 hours of deliberation in its trademark infringement suit against Pfizer, Inc. (NYSE:PFE), making it the largest judgment of its kind awarded in the United States. The trial started August 18 and the liability phase ended September 22 in a unanimous verdict for Trovan, Ltd., with the jury finding Pfizer, Inc. liable for willful, bad faith trademark infringement and unfair competition. US District Court Judge Lourdes G. Baird presided over the case. Trovan, Ltd. vs. Pfizer, Inc. [CV 98-0094 LGB (Mcx)]. Judge Baird will rule on Plaintiffsí claim that they are entitled to the profits Pfizer, Inc. earned from sales of the "Trovan" antibiotic as early as Friday.

"We are pleased with the outcome," said Joseph Masin, President of Electronic Identification Devices, "because it proves that we Davids of this world can prevail over the ëGoliathsí of this world. By finding for us, the jury sent Pfizer a clear message that they would not tolerate or excuse bad faith conduct on any level."

"Regardless of size," explained Masin, "a companyís reputation is everything. We worked hard to build Trovan® into a respectable name long before Pfizer began infringing on our trademark: and protecting that reputation was the impetus behind this lawsuit, it was never about money. With this victory, we can continue to grow our company knowing, once and for all, that Trovan® is indisputably ours."

Since 1989, Plaintiff has used the Trovan® trademark to globally market its system of biomedical electronic identification devices, and holds federal trademark registration No. 1649328 issued in 1991 by the US Patent & Trademark Office. In 1997, Trovan, Ltd. learned that Pfizer, Inc. was going to introduce and market a new antibiotic under the Trovan name, which it did in 1998, even though Plaintiff had already filed this lawsuit. In 1999, the "Trovan" antibiotic was linked to multiple possible deaths and is currently under investigation by the US Food & Drug Administration, the European Union and Ralph Naderís Public Citizen.

Trovan, Ltd. is a British corporation based in Douglas, Isle of Man, and owns the Trovan® trademark. Electronic Identification Devices, Ltd. is a California corporation based in Santa Barbara and is the exclusive North American distributor and a licensee of Trovan® products. Trovan, Ltd. also controls a portfolio of valuable patents for technology products such as RFIDs (radio frequency identification) systems, which it has most recently defended against Swiss RFID manufacturer Sokymat. In that litigation, Trovan won a judgment against Sokymat.

Press Contact: Kathy Pinckert, 310-836-8355

Trovan, Ltd. Trademark Trial against Pfizer Inc. Starts Wednesday, August 18 in Los Angeles Federal Court

Case Has Potential To Be Largest Trademark Judgment With Damages Projected in Excess of $100 Million

FOR IMMEDIATE RELEASE
August 16, 1999

Los Angeles, CA--
The Trovan, Ltd. v. Pfizer, Inc. Trial starts Wednesday, August 18 at 8:00 a.m., with voir dire beginning at 8:30 a.m., and will be heard by U.S. District Court Judge Lourdes G. Baird at the Roybal Federal Building, Room 770, 255 East Temple Street in Los Angeles. Plaintiffs Trovan, Ltd. and Electronic Identification Devices, Ltd. allege that Pfizer, Inc. (NYSE: PFE) wrongfully misappropriated their Trovan® trademark name and used it in the labeling of a new antibiotic introduced in 1998. A trial of 4-5 weeks is expected, and the case has the potential to be the largest trademark judgment ever, with damages projected in excess of $100 million.

Trovan, Ltd. has used the TROVAN® trademark since 1989 to globally market its system of biomedical electronic identification devices; holds federal trademark registration No. 164328 issued by the U.S. Patent and Trademark Office in 1991; and since 1996 has owned the Internet domain name “www.trovan.com.” TROVAN® products are used worldwide by governments, universities and research facilities for human and veterinary applications, ranging from tracking blood supplies to animal control.

“We were shocked to learn that Pfizer had allegedly applied for an identical mark with the U.S. Patent and Trademark Office to introduce its new antibiotic,” said Joseph Masin, President of Electronic Identification Devices, Ltd. “Even though we protested and had already filed suit, they launched the product with utter disregard for our established rights in the TROVAN® brand. This suit is our only recourse to prevent any further “Goliath” tactics, and we are confident that we will prevail.

“It’s likely, explained Masin, “that Pfizer invested hundreds of millions of dollars in its campaign to market “Trovan,” enabling it to become one of the most prescribed antibiotics in the United States, but at the terrible expense of our hard earned name. Damage to our reputation continues to grow, especially with recent negative publicity linking this drug to multiple possible deaths, along with talk of potential restrictions by the U.S. Food & Drug Administration and product bans by the European Union.”

In 1997, Trovan, Ltd. learned that Pfizer, Inc. Intended to introduce a new antibiotic under the identical Trovan name in 1998. Pfizer ignored their objections, and Plaintiffs filed suit for trademark infringement and unfair competition on December 8, 1997 in Santa Barbara Superior Court [Case No. 222191]. The matter was removed to the United States District Court, Central District of California, Western Division, on January 7, 1998 [Case No. CV 98-0094 LGB (Mcx)].

Trovan, Ltd. Is a British corporation and owns the trademark TROVAN® at issue; Electronic Identification Devices, Ltd. Is a California corporation based in Santa Barbara and is the exclusive North American distributor and a licensee of TROVAN® products. Plaintiffs are represented by William E. Levin with the Laguna Beach, CA law firm of Levin & Hawes.

Press Contact: Kathy Pinckert
Dial: 310-836-8355

Trial begins tomorrow in Trovan, Ltd. v. Pfizer Inc. Trademark Infringement Federal Lawsuit

MEDIA ALERT***MEDIA ALERT***MEDIA ALERT

FOR IMMEDIATE RELEASE
August 16, 1999

Los Angeles, CA--
Trial begins Wednesday, August 18, 1999 at 8:00 a.m. in the matter of Trovan, Ltd. v. Pfizer, Inc. Before the Hon. Lourdes G. Baird in U.S. District Court, Roybal Federal Building, Room 770, 255 East Temple Street, in Los Angeles, CA, with voir dire expected to start at 8:30 a.m. Followed by opening arguments. The trademark infringement and unfair competition lawsuit has the potential to be the largest trademark judgment ever, with damages projected in excess of $100 million. A 4-5 week trial is expected. Trovan, Ltd. And Electronic Identification Devices, Ltd. allege that Pfizer, Inc. Wrongfully misappropriated their Trovan® trademark name to label a new antibiotic introduced in 1998. Trovan, Ltd. has used the Trovan¨ trademark since 1989 to globally market its system of electronic identification devices for biomedical and veterinary applications; holds federal trademark registration No. 1649328 issued by the U.S. Patent & Trademark Office in 1991; and has owned the Internet domain name "www.trovan.com" since 1996. In 1997, Trovan, Ltd. Learned that Pfizer, Inc. Intended to introduce a new antibiotic in 1998 and had falsely applied for an identical mark with the U.S. Patent & Trademark Office. Over Trovan's objections and after this suit was filed, Pfizer launched a campaign to market the Trovan drug allegedly costing in the hundreds of millions of dollars; it became one of the most prescribed antibiotics in the United States, but recently has received negative publicity linking it to multiple possible deaths, along with talk of potential restrictions by the U.S. Food & Drug Administration and product bans by the European Union. Suit was filed December 8, 1997 in Santa Barbara Superior Court and removed to U.S. District Court, Central District of California, Western Division, on January 7, 1998 [Case No. CV 98-0094 LGB (Mcx)]. Trovan, Ltd. is a British corporation and owns the trademark Trovan® at issue; Joseph Masin is president of Electronic Identification Devices, Ltd., a California corporation based in Santa Barbara and the exclusive North American distributor and licensee of Trovan® products. William E. Levin with the Laguna Beach, CA law firm of Levin & Hawes represents the plaintiffs. The first day of trial starts at 8:00 a.m. Thereafter, the trial schedule is Tuesday - Friday 8:30 a.m. - 5:00 p.m., lunch Noon - 1:30 p.m.

Press Contact: Kathy Pinckert
Dial: 310-836-8355 or Pager (310) 724-9554

Court enjoins Sokymat from infringing patent, assesses $1 million judgment

FOR IMMEDIATE RELEASE
June 11, 1999

Santa Barbara, CA --
Electronic Identification Devices, Ltd. reported today that the U.S. District Court, Central District of California, Western Division, has found that defendants Sokymat S.A. and Irori infringed on U.S. Patent No. 5,281,855, issued to Trovan, Ltd., and a judgment in the amount of $1,000,000 was issued against them.

The Los Angeles Court also issued a final judgment and permanent injunction against the defendants, which prevents them from making, selling, offering for sale or using any product that infringes on U.S. Patent No. 5,281,855 in the United States. The patent describes direct bonding technology used primarily to connect antenna coils inside the transponders directly to the integrated circuit, eliminating components, and thereby lowering production costs and prices to customers and enhancing the reliability of the product. This technology is the technology of choice in automotive applications such as ignition control systems for vehicles and microtransponders used to identify animals.

The court affirmed that Sokymat S.A. et al. have no rights to U.S. Patent No. 5,281,855.

"The court's decision entitles the Plaintiffs to a comprehensive interpretation of the patent's claims" said Joseph Masin, President of Electronic Identification Devices, Ltd. "The plaintiffs will vigorously protect their intellectual property rights in all markets covered by this patent and its foreign counterparts." Trovan, Ltd. has applied for foreign counterparts in the European Patent Office, among others, including Switzerland, which is the location of Sokymat's manufacturing facility.

"We believe that the court's decision not to consider Trovan's claims of misappropriation of confidential information and title to U.S. Patent No. 5,572,410 was incorrect." said Joseph Masin. U.S. Patent No. 5,572,410, filed by Ake Gustafson, describes a machine used for coil winding and manufacture of transponders. "Based on an Agreement signed between Trovan, Ltd. and Sokymat SA, we continue to maintain that we have certain rights in U.S. Patent No. 5,572,410."

"It appears that there are presently several versions of the directly bonded product on the market," said Joseph Masin. "All versions are currently under review."

Mr. Masin has also announced that Trovan's obligations under the Agreement between Sokymat and plaintiffs dated October 20, 1998, identifying certain products, have been suspended.

For additional information in the United States please contact:
Electronic Identification Devices, Ltd.
Barbara Masin
telephone: 805-565-1288
fax: 805-565-1127
e-mail: BMasin@EIDLtd.com

Trovan Ltd. alleges fraud against Pfizer, Inc. in proposed amended complaint filed in dispute over TROVAN® Trademark

Case has potential to be the largest trademark judgment ever, with projected damages alone in excess of $100 million

FOR IMMEDIATE RELEASE
May 11, 1999

Los Angeles, CA--
Trovan, Ltd. And Electronic Identification Devices, Ltd. allege fraudulent misappropriation and use of their TROVAN® trademark by Pfizer, Inc. (NYSE: PFE) in a proposed amended complaint filed late Monday in Trovan, Ltd. v. Pfizer, Inc. They also seek to globally enjoin Pfizer from unlicensed use of the TROVAN® name in marketing a new antibiotic introduced in 1998. This antibiotic has the most indications (14) approved of by the U.S. Food and Drug Administration for a product of this type, and has already become the ninth most prescribed branded antibiotic in the United States. The case has the potential to be the largest trademark judgment ever, with projected damages alone in excess of $100 million.

"Typically, it costs hundreds of millions of dollars to introduce such a product into the marketplace", said Joseph Masin, president of Electronic Identification Devices, Ltd. "Yet, knowing that for almost seven years we had held the federal trademark registration for 'TROVAN', Pfizer went ahead and launched a major campaign to promote its new antibiotic, using our name. Then, with utter disregard for our name or international reputation. Pfizer fraudulently obtained and identical mark with the U.S. Patent and Trademark Office."

"We filed suit", explained Masin, "and since then have been in a 'David vs. Goliath' battle with Pfizer, recently defeating their Motion for Summary Judgment [under seal]. With this proposed amended complaint, we want to move forward and prevent Pfizer from further capitalizing on the TROVAN® mark worldwide or from garnering any other financial windfall through the illusion that there is any connection between our two companies, including confusion over the Internet."

Since 1989, Trovan, Ltd. Has used the TROVAN® name to market its system of electronic identification devices, and since 1991 has held federal registration No. 1649328 for the TROVAN® mark issued by the U.S. Patent and Trademark Office. TROVAN® products are used worldwide by governments, universities, and research facilities for human and veterinary applications, ranging from tracking blood supplies to animal control. Since 1996, the company's internet domain address has been: www.trovan.com.

In 1997, Trovan, Ltd. learned that Pfizer, Inc. intended to introduce a new antibiotic under the identical Trovan name in 1998. After Pfizer ignored Trovan's objections, Plaintiffs filed suit for trademark infringement and unfair competition on December 8, 1997 in Santa Barbara Superior Court [Case No. 222191]. The case was removed to the United States District Court, Central District of California, Western Division, on January 7, 1998 before the Honorable Lourdes G. Baird [Case No. 98-0094 LGB (Mcx)].

Trovan, Ltd. Is a British Corporation and owns the trademark TROVAN® at issue: Electronic Identification Devices, Ltd. Is a California corporation based in Santa Barbara and is the exclusive North American distributor and a licensee of TROVAN® products. Plaintiffs are represented by William E. Levin, with the Laguna Beach, CA law firm of Levin & Hawes.

Press Contact: Kathy Pinckert
Dial: 310-836-8355

Trovan, Ltd. Sues Pfizer for Trademark Infringement

FOR IMMEDIATE RELEASE
February 12, 1998

Santa Barbara, CA--
Electronic Identification Devices, Ltd., the North American distributor for Trovan, Ltd., and Trovan, Ltd., a UK corporation, have initiated legal action against Pfizer Inc. for trademark infringement.

Trovan, Ltd., which owns the TROVAN trademark, is a worldwide supplier of products to electronic and pharmaceutical applications marketed under its registered trademark TROVAN since 1989.

Pfizer Inc. has obtained FDA approval in December of 1997 and has begun marketing its new oral and intravenous broad-spectrum quinolone antibiotic trovafloxacin under the TROVAN trademark. According to Pfizer, the U.S. New Drug Application filed for this antibiotic was the largest ever filed by Pfizer with the FDA. Trovan, Ltd. has taken legal action to prevent unlicensed use of the TROVAN trademark by Pfizer.

Trovan, Ltd. has obtained marketing rights for a new technology which enables delivery of antibiotics and other pharmaceutica into animals or human bodies without the use of a syringe. The TROVAN delivery device, which consists of a tiny container shaped like a bullet, can be used for implanting electronic transponders for remote animal identification. The space inside the device contains a small dose of antibiotic paste, in addition to the transponder, to ward off any possible infection of the implantation site. The TROVAN delivery device can be inserted very easily simply by pressing it, sharp point first, into the animal's skin with the thumb. No tools are necessary. The implanted container will dissolve completely in the animal's tissue within three hours of insertion.

"To the uninitiated," said Mr. Dieter Salomon of Trovan, Ltd., "this device may look like it is made of a very hard, clear plastic, but the "plastic" is actually a soluble material made of a molecular compound contained in the muscle tissue of humans and animals."

The TROVAN delivery device does not make an incision, or cut, in the skin as a syringe would. Rather it pierces the skin, allowing for rapid closure of the opening after penetration, thereby minimising tissue damage and trauma.

TROVAN passive transponders are FDA approved, and have been in use for animal identification and medical tracking applications for years. The Captive Breeding Specialist Group (C.B.S.G.), an umbrella organisation for zoos and wildlife parks worldwide, has endorsed the TROVAN product in 1991 based on its unmatched performance, its small size and its low cost to the end-user. As a consequence, the Convention on International Trade of Endangered Species (C.I.T.E.S.) has voted to align itself with the C.B.S.G. recommendations in 1992, specifying that endangered fauna crossing national boundaries be identified "in accordance with the advice received from the IUCN/SCC Captive Breeding Specialist Group." Use of the TROVAN passive transponder is mandated by government agencies in a number of countries.

For additional information in the United States please contact:
Electronic Identification Devices, Ltd.
Barbara Masin
telephone: 805-565-1288
fax: 805-565-1127
e-mail: BMasin@EIDLtd.com